Belvedere Trading’s Aclaris Therapeutics ACRS Stock Holding History

Belvedere Trading’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-9,400	Closed	-$64.4K	–	791
2023 Q3	$64.4K	Buy	9,400 +1,900	+25%	+$16.2K	﹤0.01%	394
2023 Q2	$77.8K	Sell	7,500 -29,300	-80%	-$265K	﹤0.01%	472
2023 Q1	$298K	Buy	+36,800	New	+$467K	﹤0.01%	237

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Belvedere Trading's ACRS Position: Q4 2023 in Review

Belvedere Trading sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 15,386 shares — an estimated $105K sold.

Belvedere Trading first reported a position in ACRS in Q1 2021 and held it in 4 quarters. The position peaked at $415K in Q1 2021. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

Belvedere Trading reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
Belvedere Trading sold 15,386 Aclaris Therapeutics shares in Q4 2023, an estimated $105K.
Belvedere Trading first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 4 quarters.
Belvedere Trading's Aclaris Therapeutics position peaked at $415K in Q1 2021.
107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.